L3VLUP
ProSign in

IRMD · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IRMDJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IRMD
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterIRMDJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 20211 holders, $1.1m40 holders, $24.1bn
Q4 20211 holders, $32m33 holders, $25.2bn
Q1 20221 holders, $6.4m35 holders, $28.2bn
Q2 20221 holders, $5.6m33 holders, $26.9bn
Q3 20221 holders, $5.0m36 holders, $25.4bn
Q4 20221 holders, $4.7m35 holders, $27.6bn
Q1 20231 holders, $7.1m42 holders, $24.5bn
Q2 20231 holders, $8.7m38 holders, $25.0bn
Q3 20233 holders, $34m37 holders, $18.9bn
Q4 20233 holders, $36m31 holders, $19.0bn
Q1 20241 holders, $6.9m32 holders, $19.7bn
Q2 20241 holders, $6.3m35 holders, $20.4bn
Q3 20241 holders, $6.9m28 holders, $22.3bn
Q4 20241 holders, $7.8m37 holders, $20.4bn
Q1 20251 holders, $8.2m32 holders, $20.5bn
Q2 20252 holders, $11m31 holders, $18.4bn
Q3 20253 holders, $47m32 holders, $23.7bn
Q4 20253 holders, $62m29 holders, $27.8bn
Q1 20264 holders, $60m34 holders, $35.6bn
Q2 20262 holders, $38m33 holders, $39.1bn
IRMD

Iradimed Corp

Holders
1
Reported value
$6.9m
Buyers
0
Sellers
1

Breadth -1 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
32
Reported value
$19.7bn
Buyers
16
Sellers
13

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IRMD (0)

None.

Only JNJ (31)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →